| Outcome Measures: |
Primary: Change from Baseline C-peptide response in the MMTT, the proportion of participants with a positive response to the MMTT defined as C-peptide at 90 min \>0.6 ng/ml., week 4±1, week 12±2|Change from Baseline C-peptide after the MMTT, change in the area under the curve of C-peptide after the MMTT vs baseline, week 4±1, week 12±2 | Secondary: Change from Baseline insulin requirement, change in insulin requirement vs baseline, week 4±1, week 12±2|Change from Baseline fasting C-peptide, change in fasting C-peptide vs baseline, week 4±1, week 12±2|Change from Baseline HbA1c, change in HbA1c vs baseline, week 4±1, week 12±2|Adverse Events (AEs) related to the immunosuppression, the incidence and severity of Adverse Events (AEs) related to the immunosuppressive treatment, week 4±1, week 12±2|Adverse Events (AEs) and Serious Adverse Events (SAEs), Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs), week 4±1, week 12±2
|
